December 22, 2020 – Short Hills, NJ
Bayshore Pharmaceuticals is pleased to announce that it has been granted FDA-approval for its Abbreviated New Drug Applications (ANDA) for both Etodolac Immediate Release Tablets (400 mg & 500 mg) and Etodolac Extended Release Tablets (400 mg, 500 mg & 600 mg). Commercial product launch is expected to be during the first half of 2021.
